Arrowhead Pharmaceuticals Inc (ARWR) — Quality & forensics

As of 2026-09-17 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.

The Closelook module scores

46 /100 composite · 7 modules · general weight set

Valuation 13
Quality 33
Growth 79
Balance sheet 58
Cash quality 69
Capital allocation 11
Momentum 49

Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.

Financial forensics — the academic screens

6.16 Altman Z-Score

Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.

6/9 Piotroski F-Score

Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.

Continue: the ARWR chart & overview

FAQ · from the current data · as of 2026-09-17

Quick answers

What is Arrowhead Pharmaceuticals Inc's Closelook quality reading?

The composite reads 46/100 across 7 modules, as of 2026-09-17: valuation 13, quality 33, growth 79, balance sheet 58, cash quality 69, capital allocation 11, momentum 49. Closelook scores are research diary readings, not ratings or investment advice.

What is Arrowhead Pharmaceuticals Inc's Altman Z-Score?

6.16, which sits in the safe zone (above 2.99) as of 2026-09-17. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.

What is Arrowhead Pharmaceuticals Inc's Piotroski F-Score?

6 of 9, as of 2026-09-17. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.